Advanced Cell Technology plans to launch a midstage trial of its myoblast therapy during the first half of 2011, after finishing a Phase I study in heart failure patients. The Phase II trial will test the myoblast program, which involves the use of adult progenitor stem cells derived from a biopsy of skeletal muscle, in patients who are not fit to undergo bypass surgery or angioplasty.

Related Summaries